Rhythm(US:RYTM) Globenewswire·2026-03-19 22:30Core Insights - Rhythm Pharmaceuticals has received FDA approval for IMCIVREE® (setmelanotide) as the first and only therapy for acquired hypothalamic obesity, a rare condition leading to significant weight gain due to hypothalamic injury or dysfunction [2][4][10] - The approval is based on the results from the Phase 3 TRANSCEND trial, which demonstrated a statistically significant -18.4% placebo-adjusted reduction in body mass index (BMI) among participants [3][5][6] Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with IMCIVREE as its lead asset [11] - The company estimates approximately 10,000 individuals in the U.S. are affected by acquired hypothalamic obesity, highlighting a significant unmet medical need [4][10] Product Details - IMCIVREE is indicated for adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity, aiming to reduce excess body weight and maintain long-term weight reduction [3][12] - The therapy has also been approved for syndromic or monogenic obesity due to conditions such as Bardet-Biedl syndrome and POMC deficiency in patients aged 2 years and older [11][13] Clinical Trial Results - The Phase 3 TRANSCEND trial involved 142 patients, where those treated with setmelanotide achieved a -15.8% reduction in mean BMI compared to a +2.6% increase in the placebo group at 52 weeks [5][6] - Setmelanotide was generally well tolerated, with common adverse events including skin hyperpigmentation, nausea, vomiting, and headache [5][21] Support and Access - Rhythm Pharmaceuticals is committed to ensuring patient access to IMCIVREE, with a support program called Rhythm InTune that provides educational resources and assistance with insurance navigation [7] - The company will host a conference call to discuss the FDA approval and its implications for patients and healthcare providers [8]